Asian Journal of Transfusion Science最新文献

{"title":"Exploring the knowledge, attitudes, and practices on organ pledging in blood donors and nonblood donors in Northern India.","authors":"Suchet Sachdev, Kamal Kishore, Nippun Prinja, Pranay Mahajan, Pankaj Arora, Sandeep Grover, Ratti Ram Sharma, Vipin Koushal","doi":"10.4103/ajts.ajts_189_25","DOIUrl":"10.4103/ajts.ajts_189_25","url":null,"abstract":"<p><strong>Background: </strong>With advances in surgical and perfusion techniques, the demand for deceased organs is likely to increase. One way to bridge the gap between supply and demand is to increase organ pledging. Understanding knowledge deficits, attitudes, and practices can help in developing awareness programs to enhance organ pledging. Blood donors, among other populations, are more likely to engage in other prosocial behaviors and thus may be more amenable to the idea of organ donation pledging. The present study aimed to leverage the organ pledging movement through outdoor public outreach blood donation campaigns.</p><p><strong>Methods: </strong>An online cross-sectional survey among 1272 participants using a self-administered, pilot-tested, validated questionnaire that incorporated consent after preliminary information.</p><p><strong>Results: </strong>A significantly higher proportion of blood donors (75% vs. 39%, P < 0.05) reported having more information and knowledge about organ pledging, donation, and transplantation and had already pledged to donate their organs (54% vs. 43%, P < 0.05). The knowledge and practice of organ pledging and actual donation increased linearly with the number of blood donations. Most of the blood and nonblood donors agreed (88% and 84%) with the positive items, while less than half (48% and 39%) disagreed with the negative items, thereby demonstrating an overall positive attitude predisposition. The odds of pledging were 3.8 (95% confidence interval [CI], 2.69-5.61), <i>P</i> < 0.0001, and 2.5 (95% CI, 1.87-3.24), <i>P</i> < 0.0001 for respondents who had received prior counseling about organ donation and had previously donated blood.</p><p><strong>Conclusion: </strong>Structured efforts to counsel blood donors on organ pledging can provide a foundation to support a self-sustaining organ pledging program.</p>","PeriodicalId":42296,"journal":{"name":"Asian Journal of Transfusion Science","volume":"20 1","pages":"35-42"},"PeriodicalIF":0.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13290233/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148319689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Knowledge, attitude, and practice survey for patient blood management in India: An initiative by the special interest group of the Indian Society of Transfusion Medicine.","authors":"Daljit Kaur, Divjot Singh Lamba, Bharat Singh, Anil Kumar Gupta, Anupam Verma, Archana Bajpayee, Aikaj Jindal","doi":"10.4103/ajts.ajts_121_25","DOIUrl":"10.4103/ajts.ajts_121_25","url":null,"abstract":"<p><strong>Context: </strong>Patient blood management (PBM) is an evidence-based, multidisciplinary approach to optimizing transfusion practices. Despite its inclusion in global health agendas, implementation in India remains fragmented.</p><p><strong>Aims: </strong>The aim of the study was to assess the knowledge, attitude, and practice of healthcare professionals regarding PBM in India and to identify barriers to its clinical implementation.</p><p><strong>Settings and design: </strong>This was a cross-sectional, questionnaire-based online survey conducted nationwide under the aegis of the PBM special interest group of the Indian Society of Transfusion Medicine.</p><p><strong>Subjects and methods: </strong>A structured and validated 26-item questionnaire was disseminated among healthcare professionals. Responses were collected on key PBM \"components\" including clinical thresholds, anemia management, surgical planning, and postoperative strategies.</p><p><strong>Statistical analysis used: </strong>Descriptive statistics were applied. Internal consistency was measured using Cronbach's alpha. Responses were categorized to highlight major trends and challenges.</p><p><strong>Results: </strong>Out of 100 respondents, 78% were transfusion medicine specialists. While of respondents 97% acknowledged key predictors for transfusion decisions (e.g. hemoglobin, blood loss), 52% still preferred a liberal transfusion threshold of 10 g/dL, and 72% were willing to transfuse at ≥8 g/dL, which deviates from AABB guidelines. Major implementation barriers included stakeholder awareness gaps (55%), surgery delays due to PBM steps (42%), and perceived operation theatre underutilization (35%). Lack of time (73%) and test availability (69%) were less prominent challenges.</p><p><strong>Conclusions: </strong>There is a disconnect between PBM awareness and actual clinical practice in India. Advocacy, cross-specialty engagement, and regionally inclusive strategies are needed to enable evidence-based PBM adoption.</p>","PeriodicalId":42296,"journal":{"name":"Asian Journal of Transfusion Science","volume":"20 1","pages":"132-140"},"PeriodicalIF":0.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13290231/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148319745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safe blood, strong nation - The journey of India's blood transfusion services: Under Ministry of Health and Family Welfare, Government of India.","authors":"Megha Pravin Khobragade, Manas Pratim Roy, Ruchi Rao, Krishan Kumar, Madhur Gupta, Sunita Sharma","doi":"10.4103/ajts.ajts_263_25","DOIUrl":"https://doi.org/10.4103/ajts.ajts_263_25","url":null,"abstract":"<p><strong>Background: </strong>Blood transfusion services are critical for healthcare delivery, ensuring timely access to safe and adequate blood for surgeries, trauma care, obstetric emergencies, and hematological conditions. In India, BTS has witnessed remarkable progress over the past three decades under the leadership of the Ministry of Health and Family Welfare, Government of India. The system has evolved from a fragmented, donor-paid model to a nationally coordinated, policy-driven framework supported by legal mandates, national guidelines, and digital platforms such as e-RaktKosh, which have improved transparency, traceability, and operational efficiency.</p><p><strong>Materials and methods: </strong>This study reviews policy documents, national datasets, and operational guidelines from 1992 to 2025. The key sources include National Blood Transfusion Council guidelines, National AIDS Control Program documents, and e-RaktKosh analytics. Descriptive methods were used to assess the trends in blood collection, voluntary donation, infrastructure development, and quality-assurance mechanisms.</p><p><strong>Results: </strong>India's annual blood collection increased from 12.6 million units in 2023 to 14.6 million units in 2024, with continued growth anticipated in 2025. Voluntary donation reached 74.55% and 72% of blood centres had component separation units. Nucleic Acid Testing expanded substantially, with 234 centres operational nationwide. Major milestones included the ban on professional donors (1996), adoption of the National Blood Policy (2002), governance transition to Directorate General of Health Services (2021), and implementation of External Quality Assessment Scheme and Voluntary Blood Donation Guidelines (2025).</p><p><strong>Conclusion: </strong>BTS in India has transformed into a regulated, technology-enabled, policy-driven system. Continued reforms under the 2026-2031 roadmap aim to achieve 100% voluntary donation, strengthen quality standards, and ensure equitable access to safe blood across the country.</p>","PeriodicalId":42296,"journal":{"name":"Asian Journal of Transfusion Science","volume":"20 1","pages":"1-6"},"PeriodicalIF":0.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13290265/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148319791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of dithiothreitol in the resolution of pretransfusion immunohematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma.","authors":"Anshika Yadav, Pankaj Agarwal, Gajendra Nath Gupta","doi":"10.4103/ajts.ajts_146_23","DOIUrl":"10.4103/ajts.ajts_146_23","url":null,"abstract":"<p><strong>Introduction: </strong>Daratumumab (Darzalex; Janssen-Cilag Pty Ltd), an anti-CD38 monoclonal antibody (MoAb), has demonstrated high efficacy in treating relapsed and refractory multiple myeloma (MM). It stands as the pioneering anti-CD38 MoAb approved by the US FDA (2015) and TGA Australia (2017). While targeting CD38 on myeloma cells, daratumumab poses a challenge in pretransfusion testing by inducing panreactivity in indirect antiglobulin tests (IATs) due to CD38 expression on red cells. This study investigates the role of dithiothreitol (DTT) in resolving pretransfusion immunohematology testing in patients treated with daratumumab for MM.</p><p><strong>Materials and methods: </strong>Pretransfusion samples from three hematological patients diagnosed with MM and receiving anti-CD38 drugs necessitating red cell transfusion were subjected to immunohematology serological testing. Clinicians provided patient information, including gender, age, transfusion history, and time between anti-CD38 MoAb infusion and sample collection. Tests included ABO/RhD typing, IAT, both polyspecific and monospecific direct antiglobulin test (DAT), antibody (Ab) screening, Ab identification, eluate preparation, and red cell crossmatch. Control tests were conducted by incubating patient samples at 37°C for 1 h.</p><p><strong>Results: </strong>ABO/RhD typing remained unaffected, yet all samples exhibited panreactivity in IATs. Two samples showed positive DAT results but negative eluates. Treatment of reagent red blood cells (RBCs) with 0.2 M DTT effectively mitigated interference by anti-CD38 monoclonal antibodies, resulting in compatible red cell crossmatches. Notably, incubation of patient samples at 37°C for 1 h yielded identical results.</p><p><strong>Conclusion: </strong>Pretreatment of erythrocytes with DTT deactivated the CD38 antigen, eliminating reactivity with patient serum treated with daratumumab. DTT treatment of reagent RBCs emerges as an efficient and accessible strategy to counteract interference from anti-CD38 drugs in pretransfusion tests.</p>","PeriodicalId":42296,"journal":{"name":"Asian Journal of Transfusion Science","volume":"20 1","pages":"258-262"},"PeriodicalIF":0.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13290238/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148319823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A study to assess and grade the donor adverse events using the severity grading tool of hemovigilance program of India.","authors":"Punkesh Patel, Vinu Rajendran, Amita Radhakrishnan Nair, Debasish Gupta","doi":"10.4103/ajts.ajts_154_24","DOIUrl":"10.4103/ajts.ajts_154_24","url":null,"abstract":"<p><strong>Background: </strong>Donor vigilance is the monitoring of donor adverse events (DAEs) to improve donor safety and the quality of the blood donation process. This study aimed to grade and assess DAEs using a new severity grading tool (SGT) by the Hemovigilance Programme of India and to identify factors influencing it.</p><p><strong>Materials and methods: </strong>A single-center prospective observational study was conducted over 14 months among whole blood and apheresis donors with DAEs. Data was recorded in the Adverse Blood Donor Reaction Reporting Form-2 and supplemented with Blood Centre records. Data were compiled in Microsoft Excel and analyzed using DATAtab 2023.</p><p><strong>Results: </strong>Out of 11,171 registered blood donors, 7188 were eligible for donation. The overall incidence of DAEs was 288 (4.0%), out of them 0.3% occurred in predonation, 20.5% during donation, and 79.2% in postdonation. Among the DAEs, 95.8% were Grade 1, and 4.2% were Grade 2. DAEs were significantly higher in females, first-time, and apheresis donors, with increased incidence during noon time, summer season, and outdoor camps. Generalized vasovagal reactions were the most common.</p><p><strong>Conclusion: </strong>Four out of 100 donors were experiencing DAE, and the majority was of Grade 1 severity. Strategies may be adopted to mitigate DAEs among those who are predisposed to DAEs. In addition, unreported delayed DAEs are of further concern for the blood center. Our study found that SGT effectively improves the objective severity grading of DAEs. Terminologies like outside medical care are less relevant in India, where most blood donors with DAEs are managed by the medical team at the blood centre.</p>","PeriodicalId":42296,"journal":{"name":"Asian Journal of Transfusion Science","volume":"20 1","pages":"50-57"},"PeriodicalIF":0.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13290225/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148319676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A tertiary care interventional study on autologous platelet-rich plasma regenerative therapy for Grade III knee osteoarthritis.","authors":"Vinu Rajendran, Debasish Gupta, Meethu Muraleedharan, Prinu Jose, M S Saravana Babu, Nitha Jayaram, Subin Sukesan","doi":"10.4103/ajts.ajts_7_25","DOIUrl":"10.4103/ajts.ajts_7_25","url":null,"abstract":"<p><strong>Background: </strong>Platelet-rich plasma (PRP) therapy is widely used in regenerative medicine, with proven efficacy in mild-to-moderate knee osteoarthritis (OA). However, its role in advanced OA (Kellgren-Lawrence Grade III) remains uncertain.</p><p><strong>Objective: </strong>The objective of the study was to evaluate the effectiveness of PRP therapy in reducing pain and improving function in patients with Grade III bilateral knee OA.</p><p><strong>Methods: </strong>A prospective interventional study was conducted on 29 patients with Grade III bilateral knee OA. Each patient received four intra-articular PRP injections per knee (7-8 ml; 2-3 × concentration) at 4-5-week intervals. PRP was prepared using MARSPILL criteria: Non-activated, leukocyte-rich, double-spin, in a closed system, and administered within 60 min of preparation. The PRP preparation process was supervised by the transfusion medicine department. Western Ontario and McMaster Universities Arthritis Index (WOMAC) scores were recorded at baseline and at 3, 6, and 12 months posttreatment, along with monitoring for adverse events.</p><p><strong>Results: </strong>Mean WOMAC total scores improved significantly from 58.28 ± 7.7 at baseline to 27.48 ± 9.9, 26.31 ± 6.9, and 29.59 ± 7.3 at 3, 6, and 12 months, respectively (all <i>P</i> < 0.001). Significant improvements were also observed in the pain and functional difficulty subscales. No major adverse effects were reported.</p><p><strong>Conclusion: </strong>Four sessions of standardized PRP therapy significantly reduced pain and improved function in patients with bilateral Grade III knee OA for up to 1 year. This therapy may serve as a temporizing measure before definitive surgical intervention.</p>","PeriodicalId":42296,"journal":{"name":"Asian Journal of Transfusion Science","volume":"20 1","pages":"141-148"},"PeriodicalIF":0.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13290219/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148319705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of plerixafor in CD34+ stem cell mobilization in healthy pediatric stem cell donors.","authors":"Rishab Bharadwaj, Vimal Kumar, Deepti Sachan, Deepthi Krishna, Deenadayalan Munirathnam","doi":"10.4103/ajts.ajts_32_24","DOIUrl":"10.4103/ajts.ajts_32_24","url":null,"abstract":"<p><strong>Background and objectives: </strong>Efficient stem cell collection from pediatric donors is a common challenge for allogeneic hematopoietic stem cell transplants (HSCT). The addition of plerixafor, a CXCR4 antagonist to standard stem cell mobilization regimens has shown success. We describe our experience with the usage of a single dose of plerixafor in addition to granulocyte colony-stimulating factor (G-CSF) in healthy pediatric stem cell donors for patients undergoing HSCT.</p><p><strong>Materials and methods: </strong>A retrospective review of the safety and efficacy of plerixafor, used in pediatric stem cell donors for aiding stem cell mobilization, was done. Data from 14 pediatric donors who received plerixafor in addition to standard G-CSF were studied.</p><p><strong>Results: </strong>Plerixafor was well tolerated by all donors with no major adverse effects. All donors showed robust peripheral blood stem cell mobilization, enabling an adequate stem cell collection with single apheresis, even in scenarios with an unfavorable donor/patient body weight ratio.</p><p><strong>Conclusion: </strong>The use of plerixafor can be encouraged in pediatric donors to optimize apheresis outcomes.</p>","PeriodicalId":42296,"journal":{"name":"Asian Journal of Transfusion Science","volume":"20 1","pages":"170-172"},"PeriodicalIF":0.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13290183/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148319744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transfusion management in two patients with anti-f antibodies - A case report and review of the literature.","authors":"Debapriya Basu, Durba Biswas, Ayesha Sinha, Najla Haneefa Basheela, Ritam Chakrabarty, Suvro Sankha Datta","doi":"10.4103/ajts.ajts_103_23","DOIUrl":"10.4103/ajts.ajts_103_23","url":null,"abstract":"<p><p>The anti-f antibody is rarely encountered in the immunohematology laboratory. It is against the compound antigen \"ce\" or \"f.\" The \"f-\"antigen is only expressed when both c and e alleles are present in the <i>cis</i> position on the same haplotype. Anti-f is a clinically significant antibody that can cause hemolytic transfusion reaction and hemolytic disease in fetuses and newborns. Herein, we report two cases of anti-f antibodies in a 12-year-old boy with a background of bicytopenia and in an 82-year-old male patient with non-Hodgkin lymphoma. In the first case, it was an allo-anti-f associated with a warm type of autoantibody, and the second patient was suspected to have auto-anti-f. The direct antiglobulin test was positive in both cases. Both patients were transfused with c-antigen-negative compatible red cell units without any adverse reactions. This report highlighted the fact that units negative for the c-antigen are a more conservative choice for transfusion than units negative for the e-antigen as both c- and e-antigen-negative units are extremely difficult to find in the general population.</p>","PeriodicalId":42296,"journal":{"name":"Asian Journal of Transfusion Science","volume":"20 1","pages":"239-242"},"PeriodicalIF":0.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13290180/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148319796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Red blood cell alloantibodies dictating solid organ transplant decisions: Two case reports.","authors":"Soumee Banerjee, P Arpitha, T V Reddy, Santanu Chakraborty, Ankit Mathur","doi":"10.4103/ajts.ajts_167_24","DOIUrl":"10.4103/ajts.ajts_167_24","url":null,"abstract":"<p><p>Presence of antibodies directed against certain red cell antigens in a solid organ transplant recipient can complicate transplant outcome if the donor is positive for those antigen(s). Therefore, these are immunohematological barriers that affect clinical decisions taken in such scenarios. Case A: A 43 year old woman who was a case of chronic kidney disease (CKD). She was on dialysis while awaiting a renal transplant. During her pre-transplant workup, she was found to have anti-Jka and anti-e antibodies making it a challenging scenario. She was listed as a prospective match for a cadaver kidney. Complement dependant Cytotoxicity (CDC) cross-match was negative. But an additional typing was requested for the donor. When found to be Jka-, the next concern arose for any possible blood requirement during the transplant due to her anti-e antibody. Since the required units would have to be Jka-e-, a rare phenotype, it was decided to not allocate the current organ, put her back on dialysis and suitably prepare for the transplant by taking the time to correct her anemia, decide on a suitable operative strategy to minimize blood loss and attempt to arrange antigen negative units for her before the surgery. Case B: A 64 year old female patient suffered from non-alcoholic steatohepatitis(NASH) and was being considered for liver transplant from her son. However routine immunohematological testing before the transplant showed she had anti- Fya antibodies and was Fya-. Her liver donor was Fya+, but all the anticipated required red cell units needed to be Fya-. A total of 56 units were cross-matched to find 5 compatible units. Her surgery was uneventful and she required 3 units of those PRBCs during it. Red cell antigen systems should be taken into consideration in transplantations, atleast on a case-to-case basis, if not routinely, especially in the context of peri-transplant transfusion needs.</p>","PeriodicalId":42296,"journal":{"name":"Asian Journal of Transfusion Science","volume":"20 1","pages":"208-212"},"PeriodicalIF":0.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13290236/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148319780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identifying risk factors and donor characteristics for vasovagal reactions in whole blood donation: Insights and safety recommendations from a northern Indian study.","authors":"Archana Solanki, Ashutosh Singh, Atul Sonker, Prashant Agarwal","doi":"10.4103/ajts.ajts_101_25","DOIUrl":"10.4103/ajts.ajts_101_25","url":null,"abstract":"<p><strong>Background: </strong>Although adverse reactions and injuries associated with blood donation are typically self-sustaining, they may defer donors from making future blood donations.</p><p><strong>Aims: </strong>This study aimed to determine the prevalence and predictors of adverse reactions in whole blood donors, thereby identifying potential targets for interventions to reduce such events.</p><p><strong>Methods: </strong>A total of 5,003 whole blood donations were analyzed over a two-year period. Donor demographic, medical, and biometric parameters were recorded and examined for associations with adverse donor reactions.</p><p><strong>Results: </strong>The overall prevalence of vasovagal reactions was 1.7% and 287 donors (5.74%) experienced adverse events (AEs). Strong predictors of adverse reactions included younger age, first-time donation, low body weight, donation around noon, and a pre-donation waiting period exceeding 30 minutes. Vasovagal reaction rates reported in the literature vary widely, ranging from 0.09% to 2.24%. Most studies, including the present one, found no significant gender differences in reaction rates; in this study, males and females experienced almost similar rates (1.7% vs. 1.8%).</p><p><strong>Conclusion: </strong>These findings are instrumental in identifying donors at greater danger of developing undesirable reactions. Enhanced monitoring during and after donation, along with timely intervention, may facilitate to prevent many of these adverse and unpleasant events and improve donor retention.</p>","PeriodicalId":42296,"journal":{"name":"Asian Journal of Transfusion Science","volume":"20 1","pages":"126-131"},"PeriodicalIF":0.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13290260/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148319753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}